Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 43Unknown 10Terminated 7Active not recruiting 5Recruiting 3Withdrawn 2Suspended 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1CNS 1

Conditions

Breast Neoplasms 370Neoplasms 253Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 192Lung Neoplasms 142Colorectal Neoplasms 139Neoplasm Metastasis 132Pancreatic Neoplasms 131Leukemia, Myeloid, Acute 126Multiple Myeloma 123Lymphoma 115Carcinoma, Hepatocellular 111Ovarian Neoplasms 98Melanoma 97Recurrence 93Leukemia 89Head and Neck Neoplasms 89Leukemia, Lymphocytic, Chronic, B-Cell 86Brain Neoplasms 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Glioblastoma 77Lymphoma, Non-Hodgkin 73Squamous Cell Carcinoma of Head and Neck 71Lymphoma, Follicular 70Lymphoma, Large B-Cell, Diffuse 66Colonic Neoplasms 66Carcinoma, Renal Cell 62Hematologic Neoplasms 59Sarcoma 55Glioma 53

Interventions

motexafin gadolinium 1Vincristine 1Rituximab 1Radiotherapy 1Procarbazine 1Methotrexate 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Neurotoxicity Syndromes × Clear all
NCT01492920 2014-12-31

Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

GOG Foundation

Phase 3 Withdrawn
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Fatigue, Ovarian Neoplasms, Pain, Neurotoxicity Syndromes

NCT00734773 2012-05-18

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Northwestern University

Phase EARLY_PHASE1 Withdrawn
CNSLymphoid

Lymphoma, Central Nervous System Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡